Bone marrow hematopoiesis (BMH)

Bone marrow hematopoiesis is the fundamental biological process responsible for the continuous generation of all blood and immune cell lineages, including red blood cells, white blood cells, and platelets, from a reservoir of hematopoietic stem cells (HSCs) [1, 2]. This process is meticulously regulated within specialized bone marrow niches, where various stromal cells and signaling molecules, such as CXCL12 and stem cell factor, manage the balance between stem cell quiescence and differentiation [4, 11]. Dysregulation of this system is central to many life-threatening conditions, ranging from hematologic malignancies like leukemia and lymphoma to marrow failure syndromes and severe anemias [3, 8, 18]. From a therapeutic perspective, bone marrow hematopoiesis is often the target of regenerative treatments, such as recombinant growth factors (e.g., G-CSF or erythropoietin) used to restore blood counts following chemotherapy or in chronic disease [7, 9]. It also serves as a critical focus in stem cell transplantation, where drugs like plerixafor are used to mobilize HSCs for collection [14, 15]. However, the process is highly sensitive to external agents; many systemic drugs, particularly anti-cancer therapies, cause unintended myelosuppression, making the monitoring of hematopoietic health a cornerstone of clinical safety and patient management [6, 16].

Other names

Medullary hematopoiesisHemopoiesisBlood cell productionHematogenesisHematopoietic system

Drugs targeting this process primarily act through the stimulation of lineage-specific receptors such as the Granulocyte Colony-Stimulating Factor Receptor (G-CSFR), Erythropoietin Receptor (EPOR), and Thrombopoietin Receptor (MPL) to drive proliferation and maturation [7, 9]. Additionally, CXCR4 antagonists are utilized to disrupt stem cell adhesion within the bone marrow niche, facilitating the mobilization of hematopoietic stem cells into the peripheral blood for transplantation [11, 14]. Conversely, many cytotoxic agents inhibit hematopoiesis by inducing DNA damage or interfering with the cell cycle of rapidly dividing progenitor cells, leading to myelosuppression [6, 15].